2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Breast Neoplasms
4
Neoplasms
2
Somatostatinoma
1
Prostatic Neoplasms
1
Pituitary Neoplasms
1
Pancreatic Neoplasms
1
Pain
1
Lymphoma, Mantle-Cell
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Growth Hormone-Secreting Pituitary Adenoma
1
Colonic Neoplasms
1
Carcinoma, Neuroendocrine
1
Carcinoma, Merkel Cell
1
Carcinoma, Islet Cell
1
Barrett Esophagus
1
Interventions
Brentuximab Vedotin
21
Cyclophosphamide
20
fludarabine
16
Rituximab
13
Lenalidomide
13
Dexamethasone
12
fludarabine phosphate
10
Melphalan
10
Busulfan
10
Mycophenolic Acid
9
pirtobrutinib
7
dacetuzumab
7
Whole-Body Irradiation
7
Tacrolimus
7
Bortezomib
7
Doxorubicin
6
Azacitidine
6
ruxolitinib
5
Vincristine
5
Prednisone
5
Imatinib Mesylate
5
Bone Marrow Transplantation
5
ponatinib
4
pomalidomide
4
Mesna
4
Granulocyte Colony-Stimulating Factor
4
Etoposide
4
Blood Specimen Collection
4
Bendamustine Hydrochloride
4
venetoclax
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Diseases
×
Complementary Therapies
×
Clear all
NCT07541326
2026-04-21
COMPLHEMATO
University Hospital, Limoges
Phase NA
Not yet recruiting
85 enrolled